Global provider of drug development and delivery solutions to pharma and biopharma sectors, Patheon, has announced the completion of its expansion project at its Greenville site in North Carolina.
Business growth
The company has invested approximately $26 million to update one of its sterile pharmaceutical development services (PDS) suites and to build a fully integrated sterile PDF suite, which are regulatory compliant. These two suites provide 7,000 square feet of GMP manufacturing space.
“As the industry continues to innovate, customers will require even more advanced solutions, integrating development and commercial service, to meet their business needs,” said Franco Negron, president of Patheon’s drug product and pharmaceutical development services for North America. “The increasing focus on pharma to reduce costs will lead forward-thinking companies to capitalise on their core competencies — focusing on what they do best, while strategically partnering with companies such as Patheon to deliver the expertise, customised solutions and technical capabilities to support the production of their small and large molecule products.”
The newly built PDS suite will manufacture sterile liquid and lyophilised drug products and features freeze dryers and a fully integrated fitting line with a restricted access barrier system (RABS) for sterile drug products.